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ABSTRACT
Benzbromarone (BBR) is a hepatotoxic drug, but the detailed
mechanism of its toxicity remains unknown. We identified 2,6-
dibromohydroquinone (DBH) and mono-debrominated catechol (2-
ethyl-3-(3-bromo-4,5-dihydroxybenzoyl)benzofuran; CAT) as novel
metabolites of BBR in rat and human liver microsomal systems by
comparison with chemically synthesized authentic compounds,
and we also elucidated that DBH is formed by cytochrome P450
2C9 and that CAT is formed mainly by CYP1A1, 2D6, 2E1, and 3A4.
Furthermore, CAT, DBH, and the oxidized form of DBH are highly
cytotoxic in HepG2 compared with BBR. Taken together, our data
demonstrate that DBH, a novel reactive metabolite, may be relevant
to BBR-induced hepatotoxicity.
Introduction
Benzbromarone (BBR), a potent human uric acid transporter I inhibitor,
is effective in the treatment of hyperuricemia and gout, particularly when
allopurinol, an international first-line treatment, is ineffective. BBR has
long been in use in Japan (Masseoud et al., 2005) but has been
associated with hepatotoxicity, including fulminant or fatal liver injury
(van der Klauw et al., 1994). Thus, BBR is not approved for use in the
United States and has been withdrawn from the market in Europe (Lee
et al., 2008).
Adverse reactions are one of the most important issues in drug
development and in the therapeutic usage of drugs during the postapproval
stage. Specifically, unpredictable, idiosyncratic adverse drug reactions
occur only in a small group of patients who are treated with certain drugs at
therapeutic doses (Ulrich, 2007). It is widely accepted that drug-induced
idiosyncratic hepatotoxicity is often associated with cytochrome P450–
mediated bioactivation (Kalgutkar et al., 2012; Stephens et al., 2014). Thus,
BBR could be metabolized to reactive metabolites that cause liver injury.
Early metabolic studies identified that the major metabolites of BBR
are 6-hydroxybenzbromarone (6-OH-BBR) formed by cytochrome
P450 isoforms CYP2C9 and CYP2C19, and 1ʹ-hydroxybenzbromarone
(1ʹ-OH-BBR) produced by CYP3A4 (McDonald and Rettie, 2007;
Kobayashi et al., 2012). It has been reported that human hepatocarci-
noma HepG2 cells infected with adenovirus vector expressing CYP2C9
significantly increase the cytotoxicity of BBR, suggesting that CYP2C9
is associated with BBR-induced cytotoxicity (Iwamura et al., 2011).
Thus, the formation of 6-OH-BBR catalyzed by CYP2C9 was thought to
play a key role in hepatic toxicity. McDonald and Rettie (2007) proposed
that 5,6-dihydroxybenzbromarone, the secondary metabolite from
6-OH-BBR by CYP2C9, and the o-quinone form may be reactive
metabolites of BBR, although they could not show the formation of such
reactive metabolites when BBR was used as a substrate in liver
microsomal systems. Conversely, Kobayashi et al. (2013) reported that
6-OH-BBR was not cytotoxic but that BBR and 1ʹ-OH-BBR exhibited
cytotoxicity in human hepatocarcinoma FLC4 cells cultured in microspace
cells in which the expression levels of CYP2C9 and CYP3A4 had been
enhanced. They proposed that 1ʹ-OH-BBR might be the key metabolite
that causes liver injury induced by BBR. However, 1ʹ-OH-BBR is formed
predominantly by CYP3A4, and it remains unknown why CYP2C9 is
primarily responsible for BBR-induced hepatotoxicity.
In previous research, we discovered ipso-substitution as a unique
metabolic reaction of a variety of substituted phenols by cytochrome
P450 (Ohe et al., 1994, 1995, 1997, 2000; Tezuka et al., 2007; Nakamura
et al., 2011). We hypothesized that BBR, which contains a phenolic
hydroxyl group, could be oxidized to 2,6-dibromohydroquinone
(DBH) and/or mono-debrominated catechol (2-ethyl-3-(3-bromo-
4,5-dihydroxybenzoyl)benzofuran; CAT) through ipso-substitution
(Fig. 1). The formation of DBH and CAT from BBR might be linked
to the mechanism for BBR-induced hepatotoxicity because catechols,
hydroquinones, and their oxidized forms are known to be toxic via the
formation of covalent bonds with biological macromolecules and the
catalytic reduction of oxygen to superoxide and other reactive oxygen
species.
Our study elucidates the formation of ipso-substitution metabolites
in liver microsomal systems and their cytotoxicity. To this end, we
report that these metabolites may be relevant to the hepatotoxicity
induced by BBR.
This work was supported by Keio Gijuku Academic Development Funds;
a grant from the Science Research Promotion Fund of the Japan Private School
Promotion Foundation; and Platform for Drug Discovery, Informatics; and
Structural Life Science from the Ministry of Education, Culture, Sports, Science
and Technology of Japan (MEXT).
dx.doi.org/10.1124/dmd.115.065037.
s This article has supplemental material available at dmd.aspetjournals.org.
ABBREVIATIONS: BBR, benzbromarone; BSTFA, N,O-bis(trimethylsilyl)trifluoroacetamide; CAT, 2-ethyl-3-(3-bromo-4,5-dihydroxybenzoyl)benzofuran;
CYP, cytochrome P450; DBBQ, 2,6-dibromobenzoquinone; DBH, 2,6-dibromohydroquinone; G6P, glucose-6-phosphate; G6PDH, glucose-6-phosphate
dehydrogenase; GC-MS, gas chromatography with mass spectrometry; LC-MS, liquid chromatography with mass spectrometry; 1ʹ-OH-BBR,
1ʹ-hydroxybenzbromarone; 6-OH-BBR, 6-hydroxybenzbromarone; SIM, selected ion monitoring.
1303
Materials and Methods
Materials. NADP+ was obtained fromWako Pure Chemical Industries (Osaka,
Japan). Glucose-6-phosphate (G6P) and G6P dehydrogenase (G6PDH) were
obtained from Roche Diagnostics (Basel, Switzerland). Hydroquinone and N,O-bis
(trimethylsilyl)trifluoroacetamide (BSTFA) were obtained from Tokyo Chemical
Industry (Tokyo, Japan). All other reagents used for metabolism and toxicity
experiments were of analytic grade.
Synthesis of Expected Metabolites. We chemically synthesized ipso-
substituted metabolites, CAT, DBH and the oxidized form of DBH (DBBQ),
and the known main metabolite 6-OH-BBR as authentic standards for metabolite
identification and/or cytotoxicity studies. Briefly, for the synthesis of CAT, vanillin
was brominated at the 3-position with Br2 followed by methylation and oxidation
to form 3-bromo-4,5-dimethoxybenzoic acid. After treatment with SOCl2, Friedel-
Crafts acylation with 2-ethylbenzofuran was directed to the 3-position of the
benzofuran ring. Then, the demethylation reaction of the two methoxy groups with
BBr3 produced CAT.
DBH was obtained via regioselective bromination of 4-methoxyphenol with
benzyltrimethylammonium tribromide. DBBQ was directly prepared by the
oxidation of DBH using oxone (potassium peroxymonosulfate). 6-OH-BBR
was synthesized according to the procedure reported by McDonald and Rettie
(2007) with minor modifications. More detailed procedures and analytical data
for synthesized compounds are shown in Supplemental Methods.
Liver Microsomal Incubation. Phenobarbital-treated SD rat and pooled
human (200 donors) liver microsomes were purchased from XenoTech (Lenexa, KS).
The incubation mixture containing rat or human liver microsomes (1 mg protein/ml),
BBR (100 mM), MgCl2 (3 mM), G6P (10 mM), and G6PDH (1 U/ml) with or
without tienilic acid (10 mM) in 1.5 ml of 0.1 M K-Pi buffer (pH 7.4) was
preincubated for 3 minutes at 37C. The reaction was initiated by adding NADP+
(1 mM) and incubated for 30 minutes (rat) or 120 minutes (human) at 37C. We
treated 1 ml of the incubation mixture with 2 ml of ice-cold ethyl acetate to stop
the reaction and to extract the products, and the organic phase was separated.
The organic phase was dried over anhydrous Na2SO4 and concentrated by N2
flushing. The products formed were trimethylsilylated with BSTFA and pyridine.
After the removal of the excess BSTFA by N2 flushing, the residue was dissolved
in a small amount of acetone and analyzed by gas chromatography with mass
spectrometry (GC-MS) (Shimadzu GC-MS-QP5050A, capillary column HP-1
0.32 mm  30 m; J&W Scientific/Agilent Technologies, Folsom, CA). The
injection temperature was 260C. The initial column temperature was 90C for
3 minutes; then the temperature was raised at intervals of 10C/minutes to 250C,
followed by an isothermal hold at this temperature.
We treated 0.5 ml of the incubation mixture with 1 ml of acetonitrile/
methanol (2:1) to the stop the reaction. All samples were centrifuged at 10,000g
for 10 minutes, and the supernatant was analyzed by liquid chromatography
with mass spectrometry (LC-MS, 6120; Agilent Technologies, Palo Alto, CA)
Chromatographic separations were performed on XBrideShield RP18 column
(3.5 mm 2.1  150 mm) (Waters Corporation, Milford, MA) at a flow rate
0.2 ml/min under liner isocratic conditions of acetonitrile/water/HCOOH (60/
40/0.1). The eluent was introduced directly into the mass spectrometer via
electrospray ionization in the negative ion mode.
Incubation with CYP Isozymes. Recombinant human CYP isozymes
(EasyCYP Bactosomes) were purchased from Cypex (Dundee, United
Kingdom). Incubation was performed under the same conditions used for liver
microsomes described earlier, except that the incubation mixture contained 0.1 mM
CYP isozymes, 0.1 mM BBR, 4 mM MgCl2, 4 mM G6P, 1 U/ml G6PDH, and
0.4 mM NADP+.
Cell Culture. Human hepatocarcinoma HepG2 cells were obtained from
American Type Culture Collection (Manassas, VA). The HepG2 cells were
maintained in minimum essential medium (GIBCO/Life Technologies, Grand
Island, NY) containing 5% fetal bovine serum (GIBCO) and 1% penicillin-
streptomycin (Sigma-Aldrich, St. Louis, MO) in a 5% CO2 incubator with
a humidified atmosphere at 37C.
Cytotoxicity Assay. Cell toxicity was evaluated by a trypan blue dye
exclusion test. HepG2 cells were seeded (1 106 cells/ml/well) on a 96-well plate
(Iwaki/Asahi Techno Glass Corporation, Tokyo, Japan). After 24 hours of
incubation, the cells were treated with BBR, 6-OH-BBR, CAT, DBH, and DBBQ
at various concentrations. After being incubated with the drugs for 24 hours, the
Fig. 1. Proposed metabolic pathway of benzbromarone.
TABLE 1
Formation of metabolites from BBR by rat or human liver microsomal system
(nmol/nmol P450)
Each value represents the mean of three samples 6 S.D.
System 6-OH-BBR CAT DBH
Rat liver microsomes 3.05 6 0.58 1.26 6 0.15 0.07 6 0.01
Human liver microsomes 82.0 6 8.14 0.40 6 0.18 0.26 6 0.05
NADP+ (2) ND ND ND
Microsomes (2) ND ND ND
ND, not detected.
1304 Kitagawara et al.
viable cells were counted according to the dye exclusion method using Vi-Cell
(Beckman Coulter).
Results
Metabolism of BBR by Rat or Human Liver Microsomes. BBR
was incubated with phenobarbital-treated rat liver microsomes or pooled
human liver microsomes. The metabolite extracts were analyzed by LC-
MS for 6-OH-BBR and CAT and analyzed by GC-MS after
trimethylsilylation for DBH. All of the metabolites were identified on
the basis of retention time and the m/z peak ratio in selected ion
monitoring (SIM) mode, compared with the synthesized chemical
standards (6-OH-BBR, CAT, and DBH). The quantification results
including control incubations [NADP+ (2) and microsomes (2)] are
shown in Table 1. The results demonstrate that the novel metabolites
CAT and DBH were formed with rat and human hepatic microsomes.
Not all of the metabolites were detected when NADP+ or microsomes
were omitted from the complete system.
Metabolism of BBR by Isozymes of Human CYP. BBR was
incubated with various human CYP isozymes expressed in Escherichia
coli (bactosomes). The metabolite extracts were analyzed in a similar
manner to the metabolic study with liver microsomes, and the amounts
of formed metabolites were determined (Table 2). We found that the
formation of 6-OH-BBR is catalyzed by CYP1A1, CYP2C8, CYP2C9,
CYP2C19, and CYP2D6. CYP1A1, CYP2D6, CYP2E1, and CYP3A4
were found to catalyze the formation of CAT, and DBH was formed by
only CYP2C9.
Effect of CYP2C9 Inhibitor on the BBR Metabolite Formation.
Additionally, we investigated the effect of tienilic acid, a mechanism-based
inhibitor specific for CYP2C9, on the formation of three metabolites
from BBR in human liver microsomes to confirm the contribution of
CYP2C9. BBR was incubated with human liver microsomes in the
presence of 10 mM tienilic acid, and the amounts of formed metabolites
were determined. As shown in Supplemental Figure 1, the formation of
6-OH-BBR was markedly inhibited by tienilic acid, and the formation of
DBH was also significantly inhibited. In contrast, tienilic acid had no
inhibitory effect on the formation of CAT from BBR.
Cytotoxicity of BBR and BBR Metabolites in HepG2 Cells. The
cell toxicities of BBR, 6-OH-BBR, CAT, and DBH in the hepatocyte
cell line (HepG2 cells) were assessed by the use of the trypan blue dye
exclusion method after 24 hours of drug exposure. In addition, based
on the possible significance of DBH for the bioactivation process of
BBR, the toxicity of DBBQ, the oxidized form of DBH, was also
evaluated because DBH is thought to be easily oxidized to DBBQ during
incubation, although DBBQ can never be detected in the extracts from
the microsomal system because of its susceptibility to bind to
macromolecules.
The cell toxicities of the compounds at various concentrations are
demonstrated in Supplemental Figure 2. As shown in Fig. 2, the ipso-
substituted metabolites CAT, DBH, and DBBQ induced significant
cytotoxicity at the lowest concentration (0.4 mM), and they exhibited
more potent toxicity than did 6-OH-BBR. On the other hand, BBR
was not cytotoxic at this concentration.
Discussion
The exact mechanisms leading to the hepatocellular toxicity of
BBR, a therapeutically useful uricosuric drug, are not yet understood.
The present study is an attempt to elucidate the cause of BBR-induced
liver toxicity by proposing a novel bioactivation mechanism for BBR.
First, we hypothesized that BBR, which contains a phenolic hydroxyl
group, could be subject to an ipso-substitution metabolism, which we
had previously discovered as a unique metabolic pathway catalyzed by
CYP and oxidized to DBH and/or CAT.
As shown in Table 1, DBH and CAT were formed in rat and human
microsomal systems in NADPH- and microsome-dependent manners, as
determined from comparison with the synthetic standards, although the
formation amounts were much lower than that of 6-OH-BBR. The
production of CAT and DBH may be underestimated because the
recovery of these metabolites from the microsomal incubation mixtures
was shown to be low (data not shown) probably due to the covalent
binding of the oxidized forms (quinone forms) with macromolecules
such as proteins.
Isozyme profiling with recombinant CYP bactosomes clarified that
the formation of 6-OH-BBR is catalyzed by CYP1A1, CYP2C8,
CYP2C9, CYP2C19, and CYP2D6. This result is consistent with the
previous reports that CYP2C9 and CYP2C19 are the major isozymes
capable of catalyzing the formation of 6-OH-BBR (McDonald and Rettie,
2007; Kobayashi et al., 2012). CYP2C9 was also responsible for the
formation of DBH from BBR. The additional analysis using the CYP2C9
TABLE 2
Formation of metabolites from BBR by recombinant human CYP isozymes
(nmol/nmol P450)
Each value represents the mean of three samples 6 S.D.
System 6-OH-BBR CAT DBH
CYP1A1 23.9 6 2.08 0.75 6 0.02 ND
CYP1A2 ND ND ND
CYP2B6 ND ND ND
CYP2C8 60.4 6 3.3 ND ND
CYP2C9 398 6 10 ND 0.15 6 0.02
CYP2C19 193 6 33 ND ND
CYP2D6 15.3 6 1.2 1.13 6 0.07 ND
CYP2E1 ND 0.66 6 0.07 ND
CYP3A4 ND 0.88 6 0.00 ND
ND, not detected.
Fig. 2. Cytotoxicity of BBR and BBR metabolites at 0.4 mM in HepG2 cells. Cell
viability was assessed by the use of the trypan blue dye exclusion method after 24
hours of drug exposure. The data are expressed relative to control incubations
containing 0.1% DMSO alone. Each value represents the mean 6 S.D. of six
determinations from two separate experiments. ***P , 0.001 and *P , 0.05
compared with the control incubations. †††P , 0.001 and ††P , 0.01 versus the
incubations with 6-OH-BBR.
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specific inhibitor further confirmed that CYP2C9 contributes to 6-
hydroxylation of BBR and ipso-substitution metabolism to generate
DBH.
There have been some reports that CYP2C9 is primarily responsible
for BBR-induced liver toxicity. Iwamura et al. (2011) reported that
HepG2 cells infected with adenovirus vector expressing CYP2C9
significantly increase the cytotoxicity of BBR. McDonald and Rettie
(2007) suggested that the catechol metabolite 5,6-dihydroxybenzbromarone,
which is formed via 6-OH-BBR, and its o-quinone form may be
reactive metabolites and that the sequential metabolism is catalyzed by
CYP2C9, although they did not show the formation of such reactive
metabolites directly from BBR in liver microsomal systems, and their
cytotoxicity has not been elucidated.
We have demonstrated that 6-OH-BBR was cytotoxic to HepG2 cells
but the toxicity was not remarkable. Conversely, novel metabolites, DBH,
and CAT showed more potent cytotoxicity than BBR and 6-OH-BBR,
suggesting that the ipso-substituted metabolites may possibly be reactive
metabolites. In addition, the cytotoxicity of the quinone form of DBH,
DBBQ, was also examined because it is thought that DBH is easily
oxidized to DBBQ in liver microsomal systems. DBBQ also exhibited
potent cytotoxicity that is comparable to that of DBH and CAT. Taking
into consideration that DBH is mainly formed by CYP2C9, the
contribution of DBH and DBBQ to BBR-induced hepatotoxicity, in
particular, might be important.
As described earlier, Kobayashi et al. (2013) proposed that the
metabolic activation via 1ʹ-OH-BBR formed by CYP3A4 might be
responsible for BBR-induced hepatotoxicity, but the mechanism is not
yet clear; it remains unknown why CYP2C9 enhances the cytotoxicity of
BBR. Our study clearly presents an alternative mechanism for BBR-
induced hepatotoxicity activated by CYP2C9.
In conclusion, we have demonstrated the formation of reactive
metabolites in liver microsomal systems via an ipso-substitution
metabolism of BBR, which is a novel metabolic pathway for BBR.
We consider that the formation of DBH or DBBQ might be one of
the reasons for hepatocellular toxicity induced by BBR. Additional
studies to investigate the detailed mechanism for BBR-induced
hepatotoxicity are in progress.
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